A revised natural history model for primary sclerosing cholangitis.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Mayo Clinic proceedings

• Publication date

  1997-02-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.4065/75.7.688PMID 10907383
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Primary sclerosing cholangitis

  2001cited by this paper
• Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting.

  2000cited by this paper
• Optimal timing of liver transplantation for primary biliary cirrhosis

  1998cited by this paper
• Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. American College of Gastroenterology Practice Parameters Committee.

  1997cited by this paper
• Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group.

  1997cited by this paper
• Ursodiol for Primary Sclerosing Cholangitis

  1997cited by this paper
• Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases.

  1997cited by this paper
• Natural history of portal hypertension.

  1997cited by this paper
• Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding.

  1997cited by this paper
• Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study.

  1997cited by this paper
• Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.

  1996cited by this paper
• Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group.

  1996cited by this paper
• An analytic method for randomized trials with informative censoring: Part 1

  1995cited by this paper
• An analytic method for randomized trials with informative censoring: Part II

  1995cited by this paper
• Ursodeoxycholic acid in the treatment of primary biliary cirrhosis.

  1994cited by this paper
• Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis.

  1993cited by this paper
• Methods for the analysis of informatively censored longitudinal data.

  1992cited by this paper
• Primary sclerosing cholangitis: refinement and validation of survival models.

  1992cited by this paper
• Cholangiocarcinoma Complicating Primary Sclerosing Cholangitis

  1991cited by this paper
• Cholangiocarcinoma complicating primary sclerosing cholangitis.

  1991cited by this paper
• Natural history and prognostic variables in primary sclerosing cholangitis.

  1991cited by this paper
• Extramural cross‐validation of the mayo primary biliary cirrhosis survival model establishes its generalizability

  1989cited by this paper
• Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis

  1989cited by this paper
• Prognosis in primary biliary cirrhosis: Model for decision making

  1989cited by this paper
• Efficacy of liver transplantation in patients with primary biliary cirrhosis.

  1989cited by this paper
• Intrahepatic cholangiectases and large‐duct obliteration in primary sclerosing cholangitis

  1986cited by this paper
• Dependent competing risks and summary survival curves

  1983cited by this paper
• Variceal hemorrhage: a critical evaluation of survival analysis.

  1982cited by this paper
• Transection of the oesophagus for bleeding oesophageal varices

  1973cited by this paper
• The transaminase tests in liver disease.

  1967cited by this paper

• The Prognostic Utility of Quantitative Magnetic Resonance Cholangiopancreatography in Patients With PSC: A Systematic Review With Structured Evidence Synthesis.

  2026cites this paper
• Periductal iron-corrected T1 is a predictor of adverse outcomes in large-duct primary sclerosing cholangitis.

  2026cites this paper
• Novel Approaches to Cirrhosis Prognostication – Recognizing the Role of Albumin, Hepatic Encephalopathy, and Machine-Learning Models

  2026cites this paper
• Update on Biomarkers in Primary Sclerosing Cholangitis

  2026cites this paper
• Association between non-invasive biomarkers and quality of life in Primary Sclerosing Cholangitis

  2025cites this paper
• Performance of the Mayo Risk Score in Predicting Transplant and Mortality in a Single-Center U.S. Cohort of Primary Sclerosing Cholangitis

  2025influential citation
• Liver transplantation for cholestatic liver diseases: Timing & disease recurrence.

  2025cites this paper
• Radiomics‐Based Prognostication in Primary Sclerosing Cholangitis: A Proof‐of‐Concept Study

  2025influential citation
• Longitudinal Comparison of Currently Used Risk Scores for Prognostication of Primary Sclerosing Cholangitis (PSC) in a Hungarian Bicenter PSC Cohort

  2025cites this paper
• Statin Use Is Associated With Protection Against Acute Cholangitis in Patients With Primary Sclerosing Cholangitis: A Multicenter Retrospective Cohort Study

  2025cites this paper
• Does the SCOPE (Sclerosing Cholangitis Outcomes in PEdiatrics) index effectively predict later liver transplantation in children with sclerosing cholangitis?

  2025cites this paper
• Sarcopenia—A Valuable Imaging Biomarker for Disease Progression in Patients With Primary Sclerosing Cholangitis (PSC)?

  2025cites this paper
• All you need to know about the overlap between primary sclerosing cholangitis and inflammatory bowel disease

  2025cites this paper
• Faecal Cytolysin is Associated With Worse Survival in Patients With Primary Sclerosing Cholangitis

  2025cites this paper
• Imagerie par résonance magnétique des pathologies non tumorales des voies biliaires intrahépatiques de l’adulte

  2025cites this paper
• Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis

  2025cites this paper
• Systemic PCSK9 elevation characterises autoimmune liver disease across sexes

  2025cites this paper
• Mitochondrial dysfunction and lipid alterations in primary sclerosing cholangitis

  2025cites this paper
• PSC-specific prognostic scores associated with graft loss and overall mortality in recurrent PSC after liver transplantation.

  2025cites this paper
• Cholecystectomy Is Linked to Worse Clinical Outcomes in Primary Sclerosing Cholangitis

  2025cites this paper
• Validation of Quantitative Magnetic Resonance Cholangiopancreatography Metrics in Prediction of Transplant-free Survival in Primary Sclerosing Cholangitis

  2025cites this paper
• Prognostic significance of clinical scoring systems for large‐duct primary sclerosing cholangitis in Japanese patients

  2025cites this paper
• Long-term impact of scheduled regular endoscopic interventions for patients with primary sclerosing cholangitis

  2024cites this paper
• Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial

  2024cites this paper
• Disease severity prognostication in primary sclerosing cholangitis: a validation of the Anali scores and comparison with the potential functional stricture

  2024cites this paper
• Fecal deoxycholic acid associates with diet, intestinal microbes, and total bilirubin in primary sclerosing cholangitis

  2024cites this paper
• The Swedish initiative for the study of Primary sclerosing cholangitis (SUPRIM)

  2024cites this paper
• Surrogate markers of bile duct disease progression in primary sclerosing cholangitis – A prospective study with repeated ERCP examinations

  2024cites this paper
• African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitis

  2024cites this paper
• Primary Sclerosing Cholangitis Limited to Intrahepatic Bile Ducts Has Distinctly Better Prognosis

  2024cites this paper
• S2k-Leitlinie Lebertransplantation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV)

  2024cites this paper
• Natural History and Predictors of Clinical Outcomes in Autoimmune Liver Diseases: A Multicenter Study

  2024cites this paper
• Lebertransplantation bei viralen und autoimmunen Lebererkrankungen

  2024cites this paper
• Quantitative Magnetic Resonance Cholangiopancreatography Scoring and Its Predictive Value for Outcomes in Adults with Primary Sclerosing Cholangitis

  2024cites this paper
• Management of primary sclerosing cholangitis: Current state-of-the-art

  2024cites this paper
• Recent Advances in the Management of Primary Sclerosing Cholangitis.

  2023cites this paper
• A retrospective study to investigate the efficacy and safety of granulocyte and monocyte adsorptive apheresis in patients with primary sclerosing cholangitis with ulcerative colitis

  2023cites this paper
• Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study

  2023cites this paper
• Prognostic modeling in biliary diseases

  2023influential citation
• Liver Transplantation: Contraindication and Ineligibility

  2023cites this paper
• Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation.

  2023cites this paper
• Clinical factors associated with illness perception, worry and mental health in sclerosing cholangitis: a single centre prospective study.

  2023cites this paper
• Prognostic Significance of Severe Vitamin D Deficiency in Patients with Primary Sclerosing Cholangitis

  2023influential citation
• The Many Faces of Primary Sclerosing Cholangitis: Controversy Abounds

  2023cites this paper
• The challenges and potential in developing microRNA associated with regeneration as biomarkers to improve prognostication for liver failure syndromes and hepatocellular carcinoma

  2023cites this paper
• A composite score using quantitative magnetic resonance cholangiopancreatography predicts clinical outcomes in primary sclerosing cholangitis

  2023cites this paper
• Longitudinal analysis of transplant candidates with primary sclerosing cholangitis in an Asian liver transplant center

  2023cites this paper
• Interobserver agreement and prognostic value of image-based scoring systems in patients with primary sclerosing cholangitis

  2023cites this paper
• ANXA1 is identified as a key gene associated with high risk and T cell infiltration in primary sclerosing cholangitis

  2023cites this paper
• Prognostic role of magnetic resonance imaging of the abdomen with intravenous contrast and magnetic resonance cholangiopancreatography in primary sclerosing cholangitis

  2023cites this paper
• Utility of ElastPQ point-shear wave elastography in the work-up of patients with primary sclerosing cholangitis

  2023cites this paper
• Prognostic models and autoimmune liver diseases.

  2023cites this paper
• Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut–liver axis

  2023cites this paper
• [Successful pregnancy of a patient with primary sclerosing cholangitis awaiting liver transplantation].

  2023cites this paper
• Oxidative stress-related markers as prognostic factors for patients with primary sclerosing cholangitis in Japan

  2023cites this paper
• Predicting cholangiocarcinoma in primary sclerosing cholangitis: using artificial intelligence, clinical and laboratory data

  2023influential citation
• A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation

  2022cites this paper
• Quantitative magnetic resonance cholangiopancreatography metrics are associated with disease severity and outcomes in people with primary sclerosing cholangitis

  2022cites this paper
• Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis

  2022cites this paper
• Benefit of endoscopic stenting for dominant strictures in patients with primary sclerosing cholangitis

  2022cites this paper
• AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma.

  2022cites this paper
• Fenofibrate in primary sclerosing cholangitis; a randomized, double‐blind, placebo‐controlled trial

  2022cites this paper
• Protective potential of the gallbladder in primary sclerosing cholangitis

  2022cites this paper
• Patient-Predicted Outcomes Are Associated with Quality of Life in Patients with Primary Sclerosing Cholangitis

  2022cites this paper
• Clinical utility of computed tomography-based evaluation of trunk muscles in primary sclerosing cholangitis

  2022cites this paper
• Comparative Performance of Quantitative and Qualitative Magnetic Resonance Imaging Metrics in Primary Sclerosing Cholangitis

  2022cites this paper
• Impact of ulcerative colitis on liver‐related outcomes of children with primary sclerosing cholangitis

  2022cites this paper
• Serological biomarkers for management of primary sclerosing cholangitis

  2022cites this paper
• Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis

  2022cites this paper
• Bile proteome analysis by high‐precision mass spectrometry to examine novel biomarkers of primary sclerosing cholangitis

  2022cites this paper
• A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis.

  2022cites this paper
• Highly Increased Levels of Inter-α-inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver Diseases

  2022cites this paper
• Microbial manipulation as therapy for primary sclerosing cholangitis.

  2022cites this paper
• Collagen proportionate area correlates with histological stage and predicts clinical events in primary sclerosing cholangitis

  2021cites this paper
• An Examination of the Evidence Behind Biochemical Markers in Primary Biliary Cholangitis.

  2021cites this paper
• Characterization of the gut microbiota in patients with primary sclerosing cholangitis compared to inflammatory bowel disease and healthy controls

  2021cites this paper
• Evaluation of quantitative MRCP (MRCP+) for risk stratification of primary sclerosing cholangitis: comparison with morphological MRCP, MR elastography, and biochemical risk scores

  2021cites this paper
• Spatial heterogeneity of hepatic fibrosis in primary sclerosing cholangitis vs. viral hepatitis assessed by MR elastography

  2021cites this paper
• Prognosis of primary sclerosing cholangitis according to age of onset

  2021cites this paper
• Diagnosis of Primary Sclerosing Cholangitis Beyond Childhood is Associated with Worse Outcomes.

  2021cites this paper
• Transplant and Autoimmune Diseases

  2021cites this paper
• Racial differences in primary sclerosing cholangitis mortality is associated with community socioeconomic status

  2021cites this paper
• Systematic review: non‐invasive prognostic tests for primary sclerosing cholangitis

  2021cites this paper
• Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis

  2021cites this paper
• Associations of neopterin and kynurenine–tryptophan ratio with survival in primary sclerosing cholangitis

  2021cites this paper
• Endoscopic Management of Primary Sclerosing Cholangitis

  2021cites this paper
• Adult Liver Disease Prognostic Modelling for Long-term Outcomes in Biliary Atresia

  2021cites this paper
• Systematic Review of Prognostic Models Compared to the Mayo Risk Score for Primary Sclerosing Cholangitis

  2021cites this paper
• Serum IgG4 cut-off of 70 mg/dL is associated with a shorter time to cirrhosis decompensation and liver transplantation in primary sclerosing cholangitis patients

  2021cites this paper
• Value of Liver Function Tests in Cirrhosis.

  2021cites this paper
• A Quantitative Magnetic Resonance Cholangiopancreatography Metric of Intrahepatic Biliary Dilatation Severity Detects High‐Risk Primary Sclerosing Cholangitis

  2021influential citation
• Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF

  2021cites this paper
• Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis

  2021cites this paper
• Quality of life in primary sclerosing cholangitis: a systematic review

  2021cites this paper
• Primary sclerosing cholangitis.

  2021cites this paper
• Primary sclerosing cholangitis with moderately elevated serum‐IgG4 – characterization and outcome of a distinct variant phenotype

  2021cites this paper
• Primary Sclerosing Cholangitis

  2021cites this paper
• The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) Index: A Prognostic Tool for Children

  2020cites this paper
• Gadoxetic acid-enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression

  2020cites this paper
• Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning

  2020cites this paper